Oncorus Inc News - ONCR

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the...

Current Report Filing (8-k)

false000167181800016718182023-05-122023-05-12 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SEC FILE NUMBER: 001-39575 CUSIP NUMBER: 68236R103 FORM...

Current Report Filing (8-k)

false000167181800016718182023-05-022023-05-02 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Amended Annual Report (10-k/a)

YestrueNoYes--12-310001671818NoFY00016718182022-01-012022-12-3100016718182023-03-2000016718182022-06-30xbrli:sharesiso4217:USD ...

Current Report Filing (8-k)

false000167181800016718182023-04-292023-04-29 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Annual Report (10-k)

--12-310001671818three yearsfalseFY0001671818us-gaap:LeaseholdImprovementsMember2022-12-310001671818srt:Maximu...

Current Report Filing (8-k)

0001671818false00016718182023-03-242023-03-24 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit...

Current Report Filing (8-k)

false000167181800016718182023-03-142023-03-14 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER...

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Renee 1 year ago

ONCR: effective Jan. 2,2024: Company Dissolved/Final Liquidation.

FINRA will delete the symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

👍️0

Renee 2 years ago

ONCR delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

👍️0

DK11 2 years ago

Hey Bud, got in on this at 9 cents pre-market.
Looking forward to getting in on NKLA later. Have a Blessed wonderful Day.

👍️0

Invest-in-America 2 years ago

ONCR: Heck, "see what happens", INDEED!!!! (Are you using a Wall Street CRYSTAL BALL, Bro???)

That's iHub's "TRIPLE NICKLE", on the right!!!

👍️0

Louey1979 2 years ago

Why is this one running?

👍️0

Triple nickle 2 years ago

Kicking it now

👍️0

limer814 2 years ago

Grabbed some .0745 .. let's see what may happen

👍️0

Triple nickle 2 years ago

Grabbed some .1120 see what happens

👍️0

Triple nickle 2 years ago

What a dump

👍️0

reena969 2 years ago

288k shares sold, took ONCR down 18%..... guess what ... I ADDED

👍️0

reena969 2 years ago

added more ............ $81 million in cash and working with Daewoong http://crm.daewoong.co.kr/eng/what
http://crm.daewoong.co.kr/eng/who $113.15 a share

👍️0

reena969 2 years ago

AH volume...added .44

👍️0

Golden Cross 3 years ago

Agree

👍️0

lvhd 3 years ago

Low float, could run big.

👍️0

Golden Cross 3 years ago

over sold now could go way up.

👍️0

dia76ca 4 years ago

This stock deserves a board. Very interesting technology.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Oncorus Inc (ONCR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ONCR News

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

Current Report Filing (8-k)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Amended Annual Report (10-k/a)

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Ownership (sc 13g/a)

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Statement of Changes in Beneficial Ownership (4)

ONCR Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Oncorus Inc (ONCR) News

Oncorus Inc (ONCR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ONCR News

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

Current Report Filing (8-k)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Amended Annual Report (10-k/a)

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Ownership (sc 13g/a)

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Statement of Changes in Beneficial Ownership (4)

ONCR Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free